XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Moderna Collaboration and License Agreement - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2025
target
item
Jan. 31, 2022
USD ($)
product
target
Mar. 31, 2025
USD ($)
obligation
Mar. 31, 2024
USD ($)
Moderna Collaboration and License Agreement        
Collaboration revenues     $ 3,700 $ 3,400
Collaboration revenues     3,729 $ 3,397
Collaboration and License Agreement | Research and Development Services        
Moderna Collaboration and License Agreement        
Noncurrent portion of deferred revenue     41,300  
Moderna License Agreement | Research and Development Services        
Moderna Collaboration and License Agreement        
Collaboration revenues     42,400  
Moderna License Agreement | Option Right Collaboration Revenues        
Moderna Collaboration and License Agreement        
Collaboration revenues     3,800  
Moderna | Collaboration and License Agreement        
Moderna Collaboration and License Agreement        
Maximum of research targets | target   12    
Number of oncology research targets | target 12      
Number of oncology research targets, nominated | item 10      
Number of research targets, replacement nominations | target 4      
Number of oncology research targets, ceased development | target 2      
Number of nominated autoimmune target | target 2      
Moderna | Collaboration and License Agreement | Research and Development Services        
Moderna Collaboration and License Agreement        
Upfront non-refundable payment received   $ 45,000 $ 45,000  
Number of potential products to develop and commercialize | product   12    
Number of performance obligations | obligation     2  
Moderna | Collaboration and License Agreement | Research and Development Services | Minimum        
Moderna Collaboration and License Agreement        
Amount receivable per product   $ 247,000    
Moderna | Collaboration and License Agreement | Research and Development Services | Maximum        
Moderna Collaboration and License Agreement        
Amount receivable per product   $ 253,000